Citi: Downgrades target price for GIANT BIOGENE, performance at the start of Double Eleven is lukewarm

Zhitong
2025.10.17 00:56

Citi stated that the market has overreacted to GIANT BIOGENE's decline in pre-sales during Li Jiaqi's live broadcast for Double Eleven, but based on the lukewarm performance at the beginning of Double Eleven, it still lowered the company's net profit forecast and adjusted the target price down to HKD 55.4. Analyst Tiffany Feng pointed out in the report that although Li Jiaqi's live sales trend is an important indicator of Double Eleven performance, its contribution has significantly decreased. Based on industry research, despite the competition, there has been no negative feedback from customers regarding the company's products or brand. Due to weaker revenue assumptions, the net profit forecast for the company from 2025 to 2027 has been lowered by 5%-12%. The buy rating on the company is maintained

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer